Display options
Cite
Rouland L, Duplan E, Ramos Dos Santos L, et al. Therapeutic potential of parkin as a tumor suppressor via transcriptional control of cyclins in glioblastoma cell and animal models. Theranostics. 2021;11(20):10047-10063doi: 10.7150/thno.57549.
Rouland, L., Duplan, E., Ramos Dos Santos, L., Bernardin, A., Katula, K. S., Manfioletti, G., Idbaih, A., Checler, F., & Alves da Costa, C. (2021). Therapeutic potential of parkin as a tumor suppressor via transcriptional control of cyclins in glioblastoma cell and animal models. Theranostics, 11(20), 10047-10063. https://doi.org/10.7150/thno.57549
Rouland, Lila, et al. "Therapeutic potential of parkin as a tumor suppressor via transcriptional control of cyclins in glioblastoma cell and animal models." Theranostics vol. 11,20 (2021): 10047-10063. doi: https://doi.org/10.7150/thno.57549
Rouland L, Duplan E, Ramos Dos Santos L, Bernardin A, Katula KS, Manfioletti G, Idbaih A, Checler F, Alves da Costa C. Therapeutic potential of parkin as a tumor suppressor via transcriptional control of cyclins in glioblastoma cell and animal models. Theranostics. 2021 Nov 01;11(20):10047-10063. doi: 10.7150/thno.57549. eCollection 2021. PMID: 34815803; PMCID: PMC8581414.
Copy Download .nbib Format: NLM
Share it on

Theranostics. 2021 Nov 01;11(20):10047-10063. doi: 10.7150/thno.57549. eCollection 2021.

Therapeutic potential of parkin as a tumor suppressor via transcriptional control of cyclins in glioblastoma cell and animal models.

Theranostics

Lila Rouland, Eric Duplan, Lígia Ramos Dos Santos, Aurore Bernardin, Karen S Katula, Guidalberto Manfioletti, Ahmed Idbaih, Frédéric Checler, Cristine Alves da Costa

Affiliations

  1. Université Côte d'Azur, INSERM, CNRS, IPMC, team labeled "Laboratory of Excellence (LABEX) Distalz", 660 route des Lucioles, 06560, Sophia-Antipolis, Valbonne, France.
  2. Department of Biology, The University of North Carolina Greensboro, Greensboro, North Carolina, United States of America.
  3. Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.
  4. AP-HP, Service de Neurologie 2 - Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Université Pierre & Marie Curie Paris VI, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière, UMRS 975, Paris, France.

PMID: 34815803 PMCID: PMC8581414 DOI: 10.7150/thno.57549

Abstract

Parkin (PK) is an E3-ligase harboring tumor suppressor properties that has been associated to various cancer types including glioblastoma (GBM). However, PK is also a transcription factor (TF), the contribution of which to GBM etiology remains to be established.

© The author(s).

Keywords: cyclins; glioblastoma; parkin; proliferation; transcription factor

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

References

  1. STAR Protoc. 2020 Dec 15;1(3):100162 - PubMed
  2. Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2147-52 - PubMed
  3. Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):4043-8 - PubMed
  4. J Cell Biol. 2010 Aug 23;190(4):501-9 - PubMed
  5. Mol Psychiatry. 2017 Nov;22(11):1562-1575 - PubMed
  6. J Neurosci. 2006 Jun 7;26(23):6377-85 - PubMed
  7. Cell Growth Differ. 1997 Jul;8(7):811-20 - PubMed
  8. Science. 2008 Sep 26;321(5897):1807-12 - PubMed
  9. Cell Death Differ. 2003 Apr;10(4):397-9 - PubMed
  10. Genes Dev. 2007 Nov 1;21(21):2683-710 - PubMed
  11. Mol Cell Neurosci. 1996 Apr;7(4):304-21 - PubMed
  12. Mol Neurodegener. 2016 Feb 02;11:13 - PubMed
  13. J Biomed Biotechnol. 2011;2011:603925 - PubMed
  14. Pharmacol Ther. 2014 Apr;142(1):99-113 - PubMed
  15. J Neural Transm (Vienna). 2017 Sep;124(9):1037-1054 - PubMed
  16. Methods Mol Med. 2004;88:319-26 - PubMed
  17. Neuropathol Appl Neurobiol. 1998 Jun;24(3):239-45 - PubMed
  18. Cancer Res. 2012 May 15;72(10):2543-53 - PubMed
  19. J Clin Neurosci. 2005 Jan;12(1):1-5 - PubMed
  20. Nature. 2011 Jun 2;474(7349):105-8 - PubMed
  21. Science. 2002 Feb 1;295(5556):868-72 - PubMed
  22. BMC Cancer. 2008 Jan 29;8:29 - PubMed
  23. Neoplasia. 2008 Jul;10(7):634-42 - PubMed
  24. Genome Res. 2014 Dec;24(12):2059-65 - PubMed
  25. Hum Mol Genet. 2003 Sep 15;12(18):2277-91 - PubMed
  26. Nat Cell Biol. 2009 Nov;11(11):1370-5 - PubMed
  27. Mol Biol Cell. 2002 Mar;13(3):1030-45 - PubMed
  28. Mol Cell Biol. 2003 Dec;23(24):9104-16 - PubMed
  29. Biotechnol J. 2015 Apr;10(4):647-53 - PubMed
  30. Nat Genet. 2010 Jan;42(1):77-82 - PubMed
  31. Oncogene. 2014 Apr 3;33(14):1764-75 - PubMed
  32. Oncogene. 1994 Aug;9(8):2261-8 - PubMed
  33. J Mol Cell Biol. 2013 Apr;5(2):132-42 - PubMed
  34. Mol Cell. 2015 Oct 1;60(1):21-34 - PubMed
  35. Proc Natl Acad Sci U S A. 2003 May 13;100(10):5956-61 - PubMed
  36. J Cell Sci. 2013 May 1;126(Pt 9):2124-33 - PubMed
  37. Nature. 2007 Dec 6;450(7171):893-8 - PubMed
  38. Nat Genet. 2009 Jun;41(6):753-61 - PubMed
  39. J Cell Sci. 2009 Nov 15;122(Pt 22):4027-34 - PubMed
  40. Cold Spring Harb Perspect Med. 2016 Mar 01;6(3):a026104 - PubMed
  41. Int J Cancer. 2009 Nov 1;125(9):2029-35 - PubMed
  42. Oncol Lett. 2015 Sep;10(3):1716-1720 - PubMed
  43. Nat Genet. 2014 Jun;46(6):588-94 - PubMed
  44. J Biol Chem. 2000 Aug 4;275(31):24065-9 - PubMed
  45. Nat Genet. 2000 Jul;25(3):302-5 - PubMed

Publication Types